Involvement of adiponectin in the pathogenesis of dystrophinopathy by unknown
Abou-Samra et al. Skeletal Muscle  (2015) 5:25 
DOI 10.1186/s13395-015-0051-9RESEARCH Open AccessInvolvement of adiponectin in the
pathogenesis of dystrophinopathy
Michel Abou-Samra1, Sophie Lecompte1†, Olivier Schakman2†, Laurence Noel1, Marie C. Many3, Philippe Gailly2
and Sonia M. Brichard1*Abstract
Background: The hormone adiponectin (ApN) is decreased in the metabolic syndrome, where it plays a key
pathogenic role. ApN also exerts some anti-inflammatory effects on skeletal muscles in mice exposed to acute or
chronic inflammation. Here, we investigate whether ApN could be sufficiently potent to counteract a severe
degenerative muscle disease, with an inflammatory component such as Duchenne muscular dystrophy (DMD).
Methods: Mdx mice (a DMD model caused by dystrophin mutation) were crossed with mice overexpressing ApN
in order to generate mdx-ApN mice; only littermates were used. Different markers of inflammation/oxidative stress
and components of signaling pathways were studied. Global force was assessed by in vivo functional tests, and
muscle injury with Evans Blue Dye (EBD). Eventually, primary cultures of human myotubes were used.
Results: Circulating ApN was markedly diminished in mdx mice. Replenishment of ApN strikingly reduced muscle
inflammation, oxidative stress, and enhanced the expression of myogenic differentiation markers along with that of
utrophin A (a dystrophin analog) in mdx-ApN mice. Accordingly, mdx-ApN mice exhibited higher global force and
endurance as well as decreased muscle damage as quantified by curtailed extravasation of EBD in myofibers. These
beneficial effects of ApN were recapitulated in human myotubes. ApN mediates its protection via the adiponectin
receptor 1 (AdipoR1, the main ApN receptor in muscle) and the AMPK-SIRT1-PGC-1α signaling pathway, leading to
downregulation of the nuclear factor kappa B (NF-κB) and inflammatory genes, together with upregulation of
utrophin.
Conclusions: Adiponectin proves to be an extremely powerful hormone capable of protecting the skeletal muscle
against inflammation and injury, thereby offering novel therapeutic perspectives for dystrophinopathies.
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Adiponectin (ApN) is a hormone abundantly secreted by
adipocytes; its circulating levels are decreased in obesity
and in patients meeting the criteria for the metabolic syn-
drome. ApN can exhibit insulin-sensitizing, fat-burning,
and anti-inflammatory properties as well as modulatory
effects on oxidative stress [1], thereby thwarting simultan-
eously several facets of this syndrome [2].
Adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2)
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this article, unless otherwise stated.activated protein kinase (AMPK) and peroxisome
proliferator-activated receptor alpha (PPARα) pathways,
respectively. AdipoR1 is abundantly expressed in skeletal
muscle, whereas AdipoR2 is predominantly expressed in
the liver [3]. Skeletal muscle is a major target tissue of
ApN. Injection of recombinant ApN to mice or more
chronic elevation of ApN in transgenic mice clearly dem-
onstrate the potent insulin-sensitizing properties of the
molecule in vivo [4]. ApN also enhances muscle fatty acid
consumption [4]. Conversely, muscles of ApN-deficient
mice were insulin-resistant [5] and displayed higher sus-
ceptibility to oxidative stress, inflammation, and apoptosis;
all these abnormalities were exacerbated by acute or
chronic inflammatory challenge and corrected by local
electrotransfer of the ApN gene [6, 7]. Mice with muscle-article is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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resistance, decreased exercise capacity, mitochondrial
content, and oxidative metabolism, as well as enhanced
oxidative stress [8]. The presence/action of ApN is there-
fore important not only to regulate muscle fuel partition-
ing/metabolism but also to counterbalance inflammation
or cellular stress in this organ [6, 7].
Duchenne muscular dystrophy (DMD) is the most
frequently inherited human myopathy and the most dev-
astating type of muscular dystrophy. DMD stems from
X-linked recessive defects in the gene encoding for dys-
trophin, a key scaffolding protein of the dystroglycan
complex [9, 10]. This complex connects the actin cyto-
skeleton of myofibers to the extracellular matrix and is
thus crucial for maintaining cell membrane stability/per-
meability as well as normal contractile function of the
skeletal muscle. Disruption of this complex leads to
membrane damage allowing massive infiltration of im-
mune cells, chronic inflammation, necrosis, and severe
muscle degeneration [9]. Normally, muscle cells possess
the capacity to regenerate in response to injury signals.
However, this ability is progressively lost in DMD, due
to an exhaustion of satellite cells during ongoing degen-
eration/regeneration cycles [10]. Although dystrophin
mutations represent the primary cause of DMD, it is the
secondary processes involving persistent inflammation
and subsequent impaired regeneration that likely exacer-
bate disease progression [11].
The aim of this work was to explore whether ApN
may play a beneficial role in DMD. To this end,
dystrophin-deficient mdx mice, a widely used mouse
model of DMD, were crossed with our transgenic mice,
which moderately overexpress ApN [12]. These trans-
genic mice with homotopic overexpression of native
ApN showed a moderate elevation of circulating ApN
with no change in the distribution of ApN multimers
[12]. We thus examined whether the resulting mdx-ApN
mice exhibited a lower degree of muscle inflammation,
oxidative stress, and injury together with improved mus-
cular function. Lastly, we unraveled the mechanisms
underlying the protection afforded by ApN.
Methods
Animals
Transgenic C57BL/6J mice overexpressing adiponectin
(ApN mice), which had been generated in our lab, were
used; native full-length ApN was placed under the con-
trol of the adipocyte aP2 promoter, thereby targeting
ApN expression to white adipose tissue. As ApN is se-
creted, these mice also showed a moderate elevation of
circulating ApN levels [12]. C57BL/10ScSn mdx mice
were purchased from Jackson Laboratory (Maine, USA)
and crossed with ApN mice in order to obtain mdx mice
overexpressing ApN (mdx-ApN mice). Three groups of F1mice were studied in all experiments: the mdx-ApN mice,
their mdx littermates (true controls), and wild-type (WT)
mice; the three groups of mice were maintained on the
same C57BL/6J-10 ScSn genetic background. Only male
mice were studied.
These animals were maintained under a standard la-
boratory chow and housed at a constant temperature with
a fixed light-dark cycle. At the end of the experiments,
mice were sacrificed by cervical dislocation (between
09.00 and 11.00 h). Blood samples were saved. Pairs of
tibialis anterior (TA) muscles or inguinal fat pads were
weighed, frozen in liquid nitrogen, and stored at −80 °C
for subsequent analyses. For some experiments dealing
with evaluation of muscle injury, additional muscles were
sampled.
All procedures were approved by the Ethical Commit-
tee for Animal Experimentation from the Medical Sector
at the Catholic University of Louvain.
Light microscopy, immunohistochemistry, and
morphometry
Muscle samples were fixed in 10 % formalin for 24 h and
embedded in paraffin. Sections 5 μm thick were stained
with hematoxylin-erythrosin-safran (HES). The percent-
age of muscle fibers with central nuclei (a characteristic
feature of DMD) was determined on more than 1000
fibers per muscle section. For immunohistochemistry, sec-
tions were processed as previously described [6] using
rabbit polyclonal antibodies directed against peroxire-
doxin 3 (PRDX3, dilution 1:700, incubation 2 h), peroxire-
doxin 5 (PRDX5, 1:300, 2 h) [gifts from B. Knoops,
University of Louvain, Brussels, Belgium [13]], 4-hydroxy-
2-nonenal (HNE, 1:100, 2 h), tumor necrosis factor alpha
(TNFα, 1:200, 2 h), interleukin-1β (IL-1β, 1:300, over-
night), and nuclear factor kappa B (NF-κB, 1:50, over-
night) (all from Abcam, Cambridge, UK). Rat monoclonal
antibodies directed against markers of macrophages
(CD68) or of T lymphocytes (CD3) (1:50, overnight,
Abcam) were also used. Before immunostaining, sections
were submitted to heat-mediated antigen retrieval using a
microwave oven and Tris-citrate buffer (pH 6.5). Binding
of antibodies was detected by applying for 30 min at room
temperature a second antibody, which was a biotinylated
goat anti-rabbit IgG (H+L) or a biotinylated rabbit anti-rat
IgG (H+L) (Labconsult, Brussels, Belgium). Peroxidase ac-
tivity was revealed with 3,3′-diaminobenzidine (DAB)
(Life Technologies, Gent, Belgium), which produces a
brown staining. For each marker, all slides from the three
groups of mice were treated simultaneously for immuno-
histochemistry analysis and DAB revelation, and then ana-
lyzed together. Immunohistochemical controls were
performed by omission of the first antibody or of the first
and second antibodies or by using pre-immune serum.
For quantification of NF-κB expression, the percentage of
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average of 1000 fiber nuclei per slide for each mouse. For
PRDX3/5, HNE, TNFα, IL-1β, CD3, and CD68, whole
muscle section were scanned using the Leica SCN400
slide scanner (Leica Microsystems, Diegem, Belgium), and
then the percentage of DAB surface area within muscle fi-
bers was quantified using the Tissue Image Analysis 2.0
(Leica).
In vivo studies of global force or resistance
Mice were submitted to three main tests:
Wire test. Animals were suspended by their forelimbs
from a 1.5 mm-thick, 60 cm-long metallic wire at
45 cm above soft ground. The time (seconds) until the
mouse completely released its grasp and fell down was
recorded. Three trials were performed per session, with
a 30-s recovery period between trials. The maximum
time per trial was set to 180 s. For each mouse, the
scores of the three trials were averaged [14].
Grip test. The grip strength test measures the muscle
strength of forelimb or of combined fore- and hindlimb
muscles. Limb strength was recorded using a grid
connected to a sensor (Panlab-Bioseb, Vitrolles,
France). The mice were gently laid on the top of the
grid so that their front paws (forelimb test) or both
fore and hind paws (combined test) can grip the grid.
Then, mice were pulled back steadily until the grip was
released down the complete length of the grid. Each
test was repeated three times at an interval of 20 min.
Results are presented as the mean of the two highest
values of force recorded, related to body weight [15].
A third test of eccentric exercise was also performed
mainly to evaluate muscle injury (see below).
Quantification of muscle damage markers in plasma
Plasma creatine kinase (CK) and lactate dehydrogenase
(LDH) activities were quantified to evaluate skeletal
muscle damage as injured muscles release CK and LDH
into the bloodstream at high levels. Kits were based on
colorimetric methods (Gentaur, Kampenhout, Belgium).
CK and LDH activities were expressed as IU/L.
Evaluation of muscle injury after in vivo staining with
Evans blue dye
Evans blue dye (EBD) irreversibly binds to plasma albu-
min in vivo, and upon injury, the complex leaks into the
surrounding tissues [16, 17]. EBD (Sigma-Aldrich,
Bornem, Belgium) was dissolved in PBS buffer, sterilized
by filtration through membrane with pore size of
0.2 μm, and kept at 4 °C. The dye solution was injected
ip into the mice (1 mg dye/0.1 ml/10 g body weight).
The mice were sacrificed 24 h later either in basal
(sedentary) conditions or after bouts of eccentric exer-
cise [18].Eccentric exercise. The mice were subjected to a down-
hill running exercise on a treadmill with a downward in-
clination of 15°, and at a speed of 10 m/min for 10 min.
This training was repeated daily for 3 days, and the mice
were sacrificed 1 h after the 3rd session and 24 h after
the EBD injection [18]. Six different muscles were stud-
ied: biceps brachii (BB) and triceps brachii (TB) from the
forelimbs; TA, gastrocnemius (G), extensor digitorium
longus (EDL), and soleus (S) from the hindlimbs.
Spectrophotometric detection of EBD. EBD was ex-
tracted from powdered muscle using dimethylformamide,
and the absorbance was read spectrophotometrically at
620 nm. The extravasated EBD concentration was calcu-
lated against a standard curve and was expressed as ng of
EBD/mg muscle weight [16].
Fluorescence microscopy detection of EBD. Muscles
were embedded in Tissue-Tek (Sakura, Alphen-aan-den-
Rijn, Netherlands) using iso-pentane frozen in liquid
nitrogen. Three different transverse cryostat sections
(10 μm thick) were obtained for each muscle and observed
by fluorescence microscopy [17].
Western blotting and immunoprecipitation
Skeletal muscle was homogenized in a lysis buffer (Cell
Signaling Technology, BIOKE, Leiden, The Netherlands)
supplemented with 100 mM NaF and 1 % protease in-
hibitor cocktail (Active Motif, Rixensart, Belgium). Im-
munoblotting was performed as reported [19] by using
rabbit polyclonal antibodies directed against phospho-
NF-κB p65 (phosphor Ser536) and myogenic factor 5
(Myf5) (both from Abcam); AMPK, P-AMPK, and Sir-
tuin 1 (SIRT1) (all form Cell Signaling); peroxisome
proliferator-activated receptor-γ coactivator-1α (PGC-
1α) and Utrophin (both from Santa Cruz, Heidelberg,
Germany); or a mouse monoclonal antibody directed
against myogenic differentiation (MyoD) (Abcam). Sig-
nals were revealed by enhanced chemiluminescence,
then quantified and normalized to those of actin,
Ponceau stain or the studied protein without post-
translational modifications (when these modifications
were studied) using ImageJ program (National Institutes
of Health, Maryland, USA).
To obtain protein extracts for immunoprecipitation,
skeletal muscle was homogenized in the lysis buffer
indicated above, supplemented with 1 % protease/phos-
phatase inhibitor cocktail (Cell Signaling), 5 mM nico-
tinamide, and 1 mM sodium butyrate. A total of
1000 mg of proteins from muscle samples were used.
The immunoprecipitation was carried out using magnetic
beads (Thermo Fisher Scientific, Lafayette, CO) and anti-
PGC-1α antibody (2 μl antibody/1 g total protein; Santa
Cruz) following the manufacturer’s instructions. The
beads were collected using neodymium magnets and
washed with TBS-Tween 0.05 %. After the final wash, the
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(0.1 M glycine, pH 2.5); 20 μl were then separated by
SDS-PAGE and immunoblotted, as described [20], using
an acetyl-lysine antibody (1:1.000; Cell Signaling) and
anti-PGC-1α antibody (1:1.000; Santa Cruz), respectively.
Culture of human myotubes
Primary cultures of human skeletal muscle cells were
initiated from satellite cells of quadriceps samples
obtained from male organ donors (n = 5, 40 ± 9 years) or
from latissimus dorsi flap samples obtained from women
undergoing reconstructive surgery after breast cancer
(n = 6, 48 ± 13 years). The last series of biopsy samples
were used for siRNA transfection experiments. For each
patient, the culture experiments were done in duplicate
and the data from a given individual were then averaged.
Patients provided written informed consent, and the
study protocol had the approval of the local Ethical
Committee of Saint-Luc University Hospital.
Cultures were performed as described [21] with minor
modifications. Myoblasts were grown in 35-mm (or 6
wells; siRNA transfection) plates at 37 °C in the presence
of 5 % CO2 in F-12 (Ham) supplemented with 12 % fetal
bovin serum (FBS), 1 % L-glutamine, and 100 μg/ml Pri-
mocin™ (Invivogen, Toulouse, France) (all other products
from Life Technologies, Inc., Merelbeke, Belgium). After
3–5 days of proliferation, at the end of which the seed-
ing density has reached 70–80 %, the growth medium
was replaced by the fusion medium which consists of 1
part DMEM, 1 part F-12 (Ham), 2 % horse serum (HS),
1 % L-glutamine, and 1 % penicillin-streptomycin (Life
Technologies). This fusion medium was then changed
every 2 days, and differentiation was allowed to continue
for 10 days (time required to obtain mature myotubes
with characteristic elongated and multinucleated morph-
ology) before the experimentation period.
Ten days after differentiation, cells were treated with
human recombinant TNFα (10 ng/ml) + interferon
gamma (IFNγ) (10 ng/ml) and/or ApN (5 μg/ml), at the
indicated concentrations, for 24 h (TNFα from Tebu-Bio,
Boechout, Belgium, IFNγ from R&D systems, Abington,
UK, and ApN from Biovendor, Heidelberg, Germany). In
some experiments, cells were first transfected before in-
flammatory challenge and/or ApN treatment. Briefly,
3.105 cells/well were transfected with either the On-
Targetplus non-targeting pool siRNAs (negative control,
NT siRNAs), or a specific On-Targetplus siRNA SMART-
pool against human AdipoR1 (50 nM) or human SIRT1
(50 nM) or human PGC-1α (70 nM) (all from Dharma-
con, Thermo Fisher Scientific) using 7 μl Lipofectamine
RNAiMAX reagent (Life Technologies) for 24 h. siRNA
silencing was effective, ranging from 70 to 95 % in all
experiments. Next, the medium was renewed and cells
were treated with TNFα + IFNγ with or without ApNfor an additional 24 h. At the end of the experiments,
cells were collected and rinsed twice in PBS before
RNA extraction.RNA extraction and real-time quantitative PCR (RT-qPCR)
RNA was isolated from cultured cells and from mouse
adipose tissue with TriPure reagent (Roche Diagnostics,
Vilvoorde, Belgium). Of the total RNA, 1–2 μg were re-
verse transcribed, as described previously [21]. RT-qPCR
primers were designed for mouse cyclophilin, ApN as
reported [21], for interleukin 10 (IL-10; sense, 5′-TGA
TGC CCC AGG CAG AGA AGC A-3′; antisense, 3′-
GGG GAG AAA TCG ATG ACA GCG CCT C-5′), my-
osin heavy chain 7 (Myh7; sense, 5′-GGT GCC AAG
GGC CTG AAT GAG GAG-3′; antisense, 3′-GGT CTG
AGG GCT TCA CGG GCA C-5′), myosin heavy chain
1 (Myh1; sense, 5′-AGC TTC AAG TTT GGA CCC
ACG GTC G-3′; antisense, 3′-GCA GCC TCC CCG
AAA ACG GC-5′), myosin heavy chain 6 (Myh6/Mrf4;
sense, 5′-TGC GGA TTT CCT GCG CAC CT-3′; anti-
sense, 3′-GCA TCC ACG TTT GCT CCT CCT TCC-
5′), myosin heavy chain 3 (Myh3/eMyHC; sense, 5′-
CAG AAA TGG AGA CAC GGA TCA GA-3′; anti-
sense, 3′-AGA GGT GAA GTC ACG GGT CTT TGC
C-5′), myogenin (MyoG; sense, 5′-CCA GCC CAT
GGT GCC CAG TGA A-3′; antisense, 3′-TGT AGG
GTC AGC CGC GAG CAA-5′), and utrophin A (sense,
5′-GCC AGA CAC TAT GAC CCC TCC CA-3′; anti-
sense, 3′-GGG CAT GCT CAT CCT CCA CGC T-5′).
RT-qPCR primers for human TATA box-binding protein
(TBP), TNFα, interleukin-6 (IL-6) were similar to those
previously reported [22], for IκB (sense, 5′-TGT GGC
AAC TGG AAG CAA GCC C-3′; antisense, 3′-ACC
ATG GCC GCA TCA ATG TGC T-5′), and utrophin A
(sense, 5′-AGT TCC ACC AGG CAG CGG GAG-3′;
antisense, 3′-ACC TCC GTG AGA TCC GTG CTG G-
5′). Cyclophilin (mouse) and TBP (human) were used as
reporter genes. Of the total RNA equivalents, 40–80 ng
were amplified using an iCycler iQ real-time PCR detec-
tion system (Bio-Rad Laboratories, Nazareth, Belgium)
[21]. The threshold cycles (Ct) were measured in separ-
ate tubes and in duplicate. The identity and purity of the
amplified product were checked by electrophoresis on
agarose minigels, and analysis of the melting curve was
carried out at the end of the amplification. To ensure
the quality of the measurements, each plate included a
negative control for each set of primers.Result presentation and statistical analysis
Results are means ± SD for the indicated number of mice
or experiments. Comparisons between the three groups of
mice (WT, mdx, and mdx-ApN) were carried out by one-
way ANOVA followed by Tukey’s test (Prism 5; GraphPad
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mental conditions were compared in vitro, the influence
of ApN and that of TNFα/IFNγ were assessed by two-way
ANOVA with F test, followed by post hoc two by two
comparisons with Bonferroni correction for multiple com-
parisons (Prism 5). Comparisons between two myotubes
conditions from a given subject were made using two-
tailed paired Student’s t test. Differences were considered
statistically significant at P < 0.05.
Results
Characteristics of mdx mice overexpressing adiponectin
Because skeletal muscle of mdx mice exhibit
degenerative-regenerative cycles between 2 and 14 weeks
of age, we chose mid-stage mice for most experiments
[23]. We thus compared three groups of 8-week-old
mice: the mdx mice overexpressing ApN, their mdx lit-
termates (true controls), and WT mice (Table 1).
There were no significant differences in body weight
between any groups. However, as expected [24], mdx
mice presented an increase in tibialis anterior mass,
which was corrected in mdx-ApN mice (Table 1).
Remarkably, circulating ApN was decreased by ~40 %
in mdx mice compared to WT mice. This decrease was
explained by halved expression of ApN in fat tissue, the
major contributor to systemic levels. Compared to mdx
controls, plasma ApN was increased in mdx-ApN mice
(and was almost completely normalized), in line with the
3-fold rise of ApN mRNAs in adipose tissue, where the
transgene under the control of the adipocyte aP2 pro-
moter is overexpressed (Table 1) [12].
Effects of adiponectin on markers of inflammation and
oxidative stress in mdx muscles
We tested the hypothesis that ApN replenishment could
slow down the progression of dystrophic pathology by
counteracting excessive inflammation/oxidative reactions.
When compared to WT mice, myofibers from tibialis
anterior of mdx mice displayed a strong immunolabeling
for PRDX3/5, two markers of oxidative stress, and for
HNE, a lipid peroxidation product (Fig. 1). Quantifica-
tion of this immunolabeling showed that the extent ofTable 1 Characteristics of mdx mice overexpressing adiponectin
WT
Body weight (g) 22.2 ± 0.6
Tibialis anterior muscle pair weight (mg) 72 ± 2
Plasma ApN (μg/ml) 4.2 ± 0.2
Adipose tissue ApN (mRNA levels) 1.0 ± 0.2
Three groups of mice were compared at the age of 8 wks: the mdx-ApN mice (mdx
(WT) mice. Blood, tibialis anterior muscle and inguinal adipose tissue were sampled
adipose tissue by RT-qPCR. In this case, ApN gene expression was normalized to th
values. Data are means ± SD for six mice per group
*p < 0.01; **p < 0.001 compared to WT; ***p < 0.001 compared to mdxDAB staining within myofibers was ~7.5- to 9.5-fold
higher in mdx than in WT mice (see Fig. 2a–c). Qualita-
tively similar results were observed for TNFα and for IL-
1β, two pro-inflammatory cytokines (Fig. 1), with an ex-
tent of DAB staining being 11- and 6-fold greater in
mdx than in WT mice, respectively (Fig. 2d, e). In
addition, a massive infiltration of both T lymphocytes
(immunolabeling for CD3) and macrophages (CD68, a
marker of the pro-inflammatory M1 phenotype; [25])
was observed in mdx mice, but not in WT mice (Fig. 1
and Fig. 2f, g). All these indicators of oxidative stress
and inflammation were remarkably reduced in mdx-
ApN mice (Figs. 1 and 2). Serial muscle cross-sections
revealed that both myocytes and macrophages contrib-
ute to the production of pro-inflammatory cytokines. In
mdx mice, areas that were positive for C68 were nega-
tive for TNFα, while this cytokine was abundant within
the myocytes. A reverse pattern of expression was how-
ever observed for IL-1β, which was mainly produced by
macrophages and less by myocytes (Fig. 3). Remarkably,
gene expression of IL-10, an anti-inflammatory cytokine
that activates the M2 macrophage phenotype [25] was
also markedly increased in mdx-ApN mice (Fig. 2h).
Taken together, these data suggest that ApN is able to
strongly defend the skeletal muscle against excessive in-
flammatory reactions and oxidative stress.
This effect of ApN persisted later in life. In 1-year-old
mice, oxidative stress and inflammation were still blunted
in mdx-ApN muscles, as shown by reduced expression of
HNE and TNFα (Additional file 1: Figure S1).
Effects of adiponectin on markers of muscle
differentiation in mdx mice
Since ApN has been found to induce myogenesis in
C2C12 cells [26], we explored different key markers
involved in the skeletal myogenic program [25]. The
expression of MyoD and Myf5 proteins, that activate sat-
ellite cells to proliferate [25], was markedly reduced in
tibialis anterior of mdx mice when compared to WT mice
(-80 and −60 %, respectively). The decrease of these prolif-
eration markers, which may be ascribed to the inflamma-
tory context [27, 28], was partially restored in mdx-ApNmdx mdx-ApN
23.1 ± 0.7 22.2 ± 0.9
92 ± 6** 76 ± 5***
2.6 ± 0.2** 3.6 ± 0.1*/***
0.5 ± 0.1** 1.4 ± 0.2*/***
mice overexpressing ApN), their mdx littermates (true controls), and wild-type
between 09.00 and 11.00 h. ApN was measured in plasma by ELISA, and in
e levels of cyclophilin and presented as relative expression compared to WT
Fig. 1 Effects of adiponectin on different markers of oxidative stress and inflammation in muscles of mdx mice. Tibialis anterior muscles were
sampled from 8-week-old WT mice, mdx mice, or mdx mice overexpressing adiponectin (mdx-ApN). Immunodetection was performed with
specific antibodies directed against three oxidative stress markers (PRDX3/5, HNE), two pro-inflammatory cytokines (TNFα, IL-1β), one marker of
T lymphocytes (CD3), and one macrophage marker (CD68). Representative sections for six mice per group are shown. Scale bar = 25 μm (for
PRDX3/5, HNE, TNFα, and IL-1β) and 100 μm (for CD3 and CD68)
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phase), myogenin and Mrf4, were next studied. Mrf4
showed a pattern of expression similar to that of the
proliferation markers, while myogenin was increased in
mdx mice and further upregulated in mdx-ApN ones
(Fig. 4c, d). The regeneration marker, the embryonic my-
osin heavy chain (Myh3) behaved similarly (Fig. 4e).
The proportion of fibers with central nuclei, a hall-
mark of dystrophic muscle, was almost undetectable in
WT mice (<1 %), amounted to 64 % in mdx mice, and
was reduced to 49 % in mdx-ApN mice (Fig. 4f, g). Thisreduction suggests improved myogenic program and
more complete muscle regeneration.
Effects of adiponectin on global force and resistance of
mdx mice
We used two different functional tests to investigate
in vivo the global muscular force: the wire test and the
grip test. The wire test evaluates muscle force and resist-
ance to fatigue: the mouse is suspended from a horizon-
tal wire and the time until the mouse releases its grasp
is recorded [14]. Mdx mice fell down much quicker than
Fig. 2 Quantification of markers of oxidative stress and inflammation in 8-week-old mdx mice. For each immunolabeling of Fig. 1 (a–g), the
percentage of DAB deposit areas was calculated within muscle. h mRNA levels of IL-10, an anti-inflammatory cytokine. mRNA levels were
normalized to cyclophilin. Data are means ± SD for six mice per group and the subsequent ratios were presented as relative expression compared
to WT values. **p < 0.01; ***p < 0.001 vs. WT; ###p < 0.001 vs. mdx
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resistance (Fig. 5a). The grip test measures strength of
forelimb or of combined fore- and hindlimb muscles [15].
The force developed by forelimbs of mdx mice was ~36 %
lower than that of WT mice, while ApN overexpression
completely rescued forelimb strength (Fig. 5b). When
combined fore- and hindlimb force was measured, muscu-
lar strength of mdx mice was halved when compared to
WT mice, while mdx-ApN mice showed intermediate
values (Fig. 5c), indicating enhanced muscle force in the
presence of ApN.
Resistance to fatigue was evaluated by an eccentric ex-
ercise also designed to investigate muscle injury. On the
3rd day of the exercise, WT mice covered the maximum
distance (100 m), the running distance of mdx mice fell
drastically (~24 m), while that of mdx-ApN mice was
not statistically different from that of WT ones (Fig. 5d
and Additional file 2: Movie S2).Effects of adiponectin on skeletal muscle injury
Creatine kinase and lactate dehydrogenase activities, two
markers of muscle damage in plasma, measured herein in
sedentary conditions, were ~6.7- and 5.5-fold higher in
mdx than in WT mice, respectively, while both activities
declined by over 40 % in mdx-ApN mice (Fig. 5e, f ).
Sarcolemmal integrity was more directly evaluated by
using EBD. EBD extravasation was quantified in different
muscle types either in basal state (not shown) or after
repeated downhill treadmill exercise (Fig. 5g). The EBD
content of forelimbs was markedly increased in mdx
mice (7-fold for BB and 3-fold for TB) compared to WT
ones, and this content was halved in mdx-ApN mice.
Likewise, the EBD content of the four hindlimb muscles
tested was 2- to 6-fold higher in mdx mice than in WT
ones, and this increase was partially (G, EDL) or com-
pletely (TA, S) reversed by ApN overexpression (Fig. 5g).
The insets illustrate representative muscle sections
Fig. 3 Inflammation in the skeletal muscle of mdx mice. Successive sections of Tibialis anterior muscles from 8-week-old mdx and mdx-ApN mice
were stained for CD68, TNFα, and IL-1β. Representative sections for six mice per group are shown. Scale bar = 250 μm
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aged (fluorescent) fibers within each muscle corrobo-
rates the quantitative data shown in the histograms
(Fig. 5g). Hence, ApN partially or totally restored sarco-
lemmal integrity and abrogated muscle injury in each
type of skeletal muscles tested.
Effects of adiponectin on AMPK signaling pathway
Because ApN activates AMPK by binding to AdipoR1 in
muscle, thereby triggering beneficial effects on the meta-
bolic syndrome [8] and because AMPK is involved in
skeletal muscle remodeling [29], we explored the AMPK
signaling pathway.
The expression of total AMPK was similar in the three
groups of mice; however, the active phosphorylated form
was lower in the tibialis anterior muscle of mdx mice
than in WT ones (Fig. 6a). Similarly, the expression of
the deacetylase SIRT1 was markedly reduced in mdx
mice compared to WT mice (Fig. 6b). Both AMPK
phosphorylation and SIRT1 expression were completely
or partially restored in the skeletal muscle of mdx-ApN
mice (Fig. 6a, b). PGC-1α is a downstream event of thissignaling cascade. Expression of total PGC-1α was not
modified in any groups and the deacetylated form,
which is necessary for PGC-1α activation, was not
modified in mdx mice. However, mdx-ApN mice
showed a sharp (~40 %) decrease in PGC-1α acetyl-
ation (Fig. 6c). Because PGC-1α is a transcriptional co-
activator, it has the potential to alter the expression of
numerous genes. More specifically, it can induce a
myofiber shift toward a more oxidative phenotype with
increased expression of utrophin A [30, 31]. Accord-
ingly, expression of Myh7, a specific marker of slow
twitch, oxidative (type I) myofibers was increased in
tibialis anterior of mdx-ApN mice, while that of Myh1,
a marker of fast twitch, glycolytic fibers was decreased
(Fig. 6d, e). Moreover, both mRNA and protein levels of
utrophin A, an autosomal analog of dystrophin [32],
which were slightly augmented in regular mdx mice
likely to compensate the lack of dystrophin [31], were
further upregulated in mdx-ApN mice (~3–4-fold vs.
WT) (Fig. 6f, g). Taken together, these data indicate a
significant activation of the AMPK-SIRT1-PGC-1α axis
in mdx-ApN mice.
Fig. 4 Effects of adiponectin on markers of the myogenic program in mdx mice. The expression of MyoD (a) and Myf5 (b), two myogenic
regulatory factors, was analyzed by Western blotting in tibialis anterior muscles from the three groups of mice. Levels of each marker were
normalized to actin levels. mRNA levels of Mrf4 (c) and myogenin (d), two markers of muscle differentiation. e mRNA levels of Myh3 (eMyHC), a
marker of skeletal muscle regeneration. mRNA levels were normalized to cyclophilin and the subsequent ratios were presented as relative
expression compared with WT values. f Tibialis anterior sections stained with hematoxylin-erythrosin-safran. Scale bar = 100 μm. g The percentage
of muscle fibers with central nuclei was counted. Results are means ± SD; n = 6 mice per group. **p < 0.01; ***p < 0.001 vs. WT; ##p < 0.01; ###
p < 0.001 vs. mdx mice
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Fig. 5 Effects of adiponectin on global force, resistance and muscle injury in mdx mice. Functional in vivo studies were carried out in mice from the
three groups. a The animals were subjected to a wire test where they were suspended by their forelimbs and the time until they completely released
the wire and fell down was recorded (seconds). b, c The mice were also lowered on a grid connected to a sensor to measure the muscle force of their
forelimbs (b) or of both fore- and hindlimbs (c); data were then expressed in gram-force relative to body weight (gf/g BW). d Mice were submitted to
a downhill treadmill exercise for 10 min during three consecutive days. On the 3rd session, the covered distance (meters) were measured for each
mouse, 100 m being the maximal distance. Muscle injury was assessed by plasma activity of CK and LDH expressed as IU/L (basal state) (e, f) and by
using EBD (g). Quantification of EBD extravasation was measured in different muscles after exercise. Six different muscles were sampled: biceps brachii,
triceps brachii, gastrocnemius, tibialis anterior, extensor digitorium longus, and soleus. Qualitative detection of EBD was evaluated by fluorescence
microscopy on frozen cryostat sections (see insets above histograms). Extravasated EBD concentrations were also quantified spectrophotometrically
after extraction of the dye. Data were expressed as ng of EBD/mg muscle weight. The results presented herein are the means ± SD; n = 9 (a–c) and six
(d–g) mice per group. ***p < 0.001 vs. WT ; ###p < 0.001 vs. mdx mice
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NF-κB is a pleiotropic transcription factor modulating
immune, inflammatory, survival, and proliferative re-
sponses [11]. To further characterize the molecular
mechanisms responsible for the protective effects of
ApN, we examined NF-κB activity by two different
approaches.
First, we measured the nuclear translocation of NF-κB
p65 subunit. Tibialis anterior sections were immunola-
beled and the percentage of NF-κB marked nuclei in
myofibers was counted: this percentage was 4.5-fold
higher in mdx than in WT mice, but this rise was halved
in mdx-ApN mice (Fig. 6h, i). Second, we quantified the
active phosphorylated form of NF-κB (P-p65 on Ser536)
by Western blot (Fig. 6j). P-p65 activation was ~4-fold
higher in tibialis anterior of mdx mice than in WT mice,
and this enhanced activation was again halved in mdx-
ApN mice. Hence, the hyperactivity of NF-κB in muscles
of mdx mice was attenuated by ApN. This effect per-
sisted in old mice (Additional file 1: Figure S1D).Effects of adiponectin on inflamed human myotubes
Finally, we tested the direct effects of ApN in primary
cultures of human myotubes. Because TNFα expression
was markedly elevated in muscles of mdx mice, and to
mimic the inflammatory microenvironment of DMD, we
challenged the myotubes with an inflammatory stimulus
(TNFα/IFNγ) (Fig. 7). TNFα combined with IFNγ in-
duced its own gene expression and that of another in-
flammatory cytokine, IL-6. ApN treatment abrogated
these inductions (Fig. 7a, b).
Consistent with this, ApN reduced the rise of TNFα
mRNAs in response to this pro-inflammatory cocktail or
increased the mRNA levels of IκB (an inhibitor of NF-
κB) in the presence of non-targeting (NT) siRNAs [com-
pare the first two histograms (black vs. white column) of
each panel; (Fig. 7c, d)]. These anti-inflammatory effects
of ApN were abolished by siRNA silencing of genes en-
coding for either AdipoR1, SIRT1, or PGC-1α (Fig. 7c, d).
Hence, each of these components appears to be necessary
for the anti-inflammatory action of ApN (Fig. 8).In this inflammatory setting, ApN treatment also
slightly upregulated utrophin A mRNA in human myo-
tubes with intact dystrophin (Fig. 7e).Discussion
A crucial finding of this study is that we evidenced a de-
crease of ApN in mdx mice. Another novel observation
is that ApN correction yields striking and long-lasting
attenuation of muscle inflammation and injury and im-
proves muscle function.
We unambiguously showed that plasma ApN is de-
creased in mdx mice, in line with recent serum prote-
ome data, which were however qualitative and obtained
in a very limited number (n = 3) of mdx mice [33]. Such
a decrease is relevant as it may justify therapeutic cor-
rection. We further demonstrated that it may be as-
cribed to reduced ApN production by fat tissue, the
main contributor to systemic levels. This reduced pro-
duction may in turn result from the systemic inflamma-
tory environment in DMD [34]. TNFα indeed repressed
ApN expression in adipocytes [35]. By contrast, circulat-
ing ApN was almost normalized in mdx-ApN mice due
to homotopic overexpression of ApN.
As a result, mdx-ApN mice exhibited marked reduc-
tion of muscular inflammation as shown by decreased
expression of pro-inflammatory cytokines and lower in-
filtration by both T-lymphocytes and macrophages. As in
other tissues [36], ApN could also promote in muscle
macrophage polarization toward an anti-inflammatory
phenotype as suggested by decreased expression of
CD68, a M1 marker and increased expression of IL-10,
which activates the anti-inflammatory and tissue-healing
M2 phenotype. Markers of oxidative stress were also re-
duced in mdx-ApN mice. All these data are in agree-
ment with our previous study carried out in ApN-KO
mice, which exhibited a contrario higher signs of muscu-
lar inflammation and oxidative stress, which were cor-
rected by muscular electrotransfer of the ApN gene [6].
Herein, we further show that the presence of ApN is
crucial to counterbalance inflammation and oxidative
stress in skeletal muscle even when this inflammation is
Fig. 6 (See legend on next page.)
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Fig. 6 Effects of adiponectin on AMPK signaling pathway and NF-κB activity in tibialis anterior muscles of mdx mice. The expression of P-AMPK
(phosphorylated form) (a) and SIRT1 (b) was analyzed by Western blotting in muscles from the three groups of mice. c Densitometry of
immunoprecipitation experiments performed on skeletal muscle lysates, using anti-PGC-1α antibody for precipitation and anti-acetyl-lysine
antibody for immunoblotting. d mRNA levels of Myh7, a marker of slow twitch, oxidative myofibers. e mRNA levels of Myh1, a marker of fast
twitch, glycolytic myofibers. f mRNA and g protein levels of utrophin A (UTRN) with a representative Western blot and Ponceau S stain.
h Immunodetection of NF-κB (p65) in tibialis anterior sections; some positive marked nuclei (brown color) are indicated by arrows. Scale
bar = 25 μm. i Quantification of p65 immunolabeling in myofiber nuclei (expressed as percent of total nuclei) in sections (as those shown in
g). j Immunoblotting of phosphorylated NF-κB p65 in the same muscles. Levels of P-AMPK, SIRT1, and Acetyl-Lys were normalized to AMPK,
actin, and PGC-1α levels, respectively. mRNA levels were normalized to cyclophilin, utrophin A protein levels to Ponceau, and P-p65 to Actin.
The subsequent ratios were presented as relative expression compared to WT values. Results are means ± SD; n = 6 mice per group. *p < 0.05;
**p < 0.01; ***p < 0.001 vs. WT; ###p < 0.001 vs. mdx mice
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muscle.
Besides its anti-inflammatory properties, ApN also
positively affects the skeletal myogenic program. ApN
has been reported to activate muscle satellite cells,
which are major participants in muscle regeneration [37]
and to induce differentiation and fusion of C2C12 myo-
blasts [26]. Herein, the skeletal muscle of mdx-ApN
mice displayed partial or complete restoration of MyoD
and Myf5, two positive regulatory factors of the prolifer-
ative stage [27, 28] as well as of Mrf4, a regulator of the
early differentiation phase [25]. Myogenin, another
marker of this early differentiation phase, was even up-
regulated. Taken together, these data indicate a more ef-
ficient skeletal myogenic program in mdx-ApN mice.
Both anti-inflammatory and myogenic properties may
contribute to ApN protection against muscle injury.
Upregulation of utrophin may also be a crucial contribu-
tor. Thus, ApN overexpression strikingly reduced both
plasma CK and LDH levels and fiber membrane damage
in all dystrophic muscles, as shown by in vivo staining
with EBD. Accordingly, mdx-ApN mice improved global
muscular force and exercise endurance in vivo. Con-
versely, ApN-KO mice exhibited lower peak tetanic
forces in muscles stimulated in situ, while mice with
muscle-specific disruption of AdipoR1 showed reduced
treadmill exercise endurance [8, 38].
Although the anti-diabetic and metabolic effects of ApN
are well described in skeletal muscle, the mechanisms
underlying its anti-inflammatory/protective properties are
only poorly studied. These molecular mechanisms were
therefore investigated ex vivo and in vitro. As we did not
find overt signs of apoptosis in our 8-week-old mdx mice
(data not shown), we did not explore the sphingolipid cer-
amide pathway [39] but rather the AMPK axis. Phosphor-
ylated AMPK and SIRT1 expression were reduced in
skeletal muscle of mdx mice, while ApN partially or com-
pletely restored these levels. The activity of PGC-1α is en-
hanced by AMPK via phosphorylation and by SIRT1 via
deacetylation [8]. Here, ApN stimulated PGC-1α deacetyla-
tion in mdx mice. Stimulation of the AMPK-SIRT1-PGC-1α
may protect against muscle dystrophy by activating severalbiological processes [30]. First is upregulation of utrophin
A together with the induction of a muscle fiber shift
toward a more oxidative phenotype. Recent work has
shown that pharmacological interventions (AICAR,…)
that induce a more oxidative phenotype conferred mor-
phological and functional improvements in mdx mice
[31]. However, the induction of utrophin A appears to
be a prerequisite to observe these benefits, which were
detectable only in mdx mice, but not in double-KO
mice (mdx mice which were also deficient in utrophin).
Several studies have reported that utrophin can restore
sarcolemmal integrity and serve as a surrogate to dys-
trophin in dystrophic muscle [32]. In this paper, utro-
phin appears to be a new target of ApN. Second is
repression of NF-κB activity. PGC-1α has been reported
to repress the phosphorylation of NF-κB family mem-
ber p65, thereby inhibiting its transcriptional activity
and subsequent pro-inflammatory cytokine production
in C2C12 cells [40]. SIRT1 could also suppress NF-κB
signaling via deacetylation of the p65 subunit [41].
Repressing NF-κB activity is relevant in the context of
dystrophinopathy: on one hand, NF-κB signaling is per-
sistently elevated in DMD mouse models and patients
[11], and suppresses the myogenic program [27, 28]; on
the other hand, inhibiting this pathway has been re-
ported to exert protective effects in mouse models of
muscle injury [11, 42]. We also originally found that
AdipoR1 as well as SIRT1 and PGC-1α were crucial
components of the anti-inflammatory action of ApN in
human myotubes, a finding that seems to be verified in hu-
man dystrophic muscle cells (S. Lecompte, M. Abou-Samra,
R. Boursereau, L. Noel, S.M. Brichard: Anti-inflammatory
potential of Adiponectin in human dystrohic myotubes,
in preparation). Third, additional biological processes
not studied herein could also participate (like ApN- [5]
and AMPK-mediated autophagic removal of dysfunc-
tional proteins [29]). Taken together, our data suggest
that ApN exerts its protective effects on skeletal
muscle, by binding to AdipoR1 and activating the
AMPK-SIRT1-PGC-1α pathway, thereby leading to NF-
κB repression and utrophin upregulation (Fig. 8). Com-
pared to other pharmacological agents targeting this
Fig. 7 Effects of adiponectin on inflammatory markers in human skeletal muscle. TNFα (a) and IL-6 (b) mRNAs in primary culture of human myotubes:
cells were treated with or without ApN, while being or not challenged with TNFα and IFNγ. TNFα (c) and IκB (d) mRNAs in human myotubes, which
were transfected with siRNAs against AdipoR1, SIRT1, PGC-1α, or a negative (non-targeting, NT) control. After transfection, cells were treated with or
without ApN, while being challenged with TNFα/IFNγ. mRNA levels were normalized to TATA box-binding protein. The subsequent ratios are
presented as relative expression compared to control conditions [i.e., no TNFα/IFNγ and no ApN (a, b); NT siRNA without ApN (c, d)]. e Utrophin A
mRNAs in human myotubes, which were treated with or without ApN, while being challenged with TNFα and IFNγ. mRNA levels were normalized as
above. In this last graph, each patient is represented as being its own control (statistical analysis was performed on raw paired data). Data are means ±
SD; n = 5–6 different subjects. **p < 0.01; ***p < 0.001 vs. no TNFα/IFNγ; ###p < 0.001 vs. TNFα/IFNγ without ApN; §§§p < 0.001 vs. all other conditions
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Fig. 8 Proposed model for the protective effects of adiponectin on dystrophic muscle. Signal transduction mediating ApN protection on
dystrophic muscle: binding of ApN to AdipoR1 activates the AMPK/SIRT1/PGC-1α pathway. Briefly, ApN leads to AMPK phosphorylation/activation.
P-AMPK in turn phosphorylates PGC-1α and indirectly increases the expression of SIRT1 (through rising NAD+/NADH ratio). SIRT1 in turn deacetylates and
fully activates PGC-1α. Next, PGC-1α represses NF-κB activity by dephosphorylation of the p65 subunit [38], while SIRT1 represses it by deacetylation [39].
This results in decreased muscle inflammation/oxidative stress and improved myogenic program as well as enhanced utrophin expression and oxidative
capacity, both processes helping rescue the dystrophic phenotype. Green arrow, stimulation; red arrow, inhibition
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the improvement brought about by ApN, at physio-
logical concentrations, is impressive and long-lasting.
The only medications so far shown to be effective in
delaying the progression of DMD are glucocorticoids
[43, 44]. However, adverse effects of glucocorticoids
must be considered: growth retardation and weight gain,
bone demineralization and fracture risk, cataracts, as
well as behavioral disturbance in DMD boys. Other sideeffects involve glucose intolerance, hypertension,
gastrointestinal problems, and Cushingoid appearance
[43, 45]. Conversely, long-term treatment with ApN,
which has been tested so far only in mouse, was not
accompanied by major side effects. Transgenic mice
overexpressing human adiponectin even showed increased
longevity, which was ascribed to attenuation of oxidative
DNA damage [46]. ApN may offer several other advan-
tages over glucocorticoids. Unlike glucocorticoids, ApN
Abou-Samra et al. Skeletal Muscle  (2015) 5:25 Page 16 of 17increases insulin sensitivity [4], does not induce muscle at-
rophy but rather reduces proteolysis [47], upregulates
utrophin (our own data) and enhances the myogenic pro-
gram, prevents obesity [12, 46], and protects against
hypertension [48].
Conclusions
Adiponectin proves to be an extremely powerful hor-
mone that protects muscle against inflammation, oxida-
tive stress, and injury, even when the abnormalities are
extremely severe and long-lasting such as in dystrophic
muscle. This raises new therapeutic perspectives not
only in myopathy but also in several other diseases, in
which excessive inflammation plays a triggering or wors-
ening pathogenic role.
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